Follow
Mitchell Gross
Mitchell Gross
Verified email at usc.edu
Title
Cited by
Cited by
Year
A transcriptional corepressor of Stat1 with an essential LXXLL signature motif
B Liu, M Gross, J ten Hoeve, K Shuai
Proceedings of the National Academy of Sciences 98 (6), 3203-3207, 2001
2682001
Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years
D Bahn, AL de Castro Abreu, IS Gill, AJ Hung, P Silverman, ME Gross, ...
European urology 62 (1), 55-63, 2012
2482012
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer
EY Yu, G Wilding, E Posadas, M Gross, S Culine, C Massard, MJ Morris, ...
Clinical Cancer Research 15 (23), 7421-7428, 2009
2432009
Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone
JE Rosenberg, VK Weinberg, WK Kelly, D Michaelson, MH Hussain, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2007
2312007
Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells
M Gross, B Liu, J Tan, FS French, M Carey, K Shuai
Oncogene 20 (29), 3880-3887, 2001
2082001
3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound …
O Ukimura, MM Desai, S Palmer, S Valencerina, M Gross, AL Abreu, ...
The Journal of urology 187 (3), 1080-1086, 2012
1812012
Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells
AE Dago, A Stepansky, A Carlsson, M Luttgen, J Kendall, T Baslan, ...
PloS one 9 (8), e101777, 2014
1582014
Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer
H Jadvar, B Desai, L Ji, PS Conti, TB Dorff, SG Groshen, ME Gross, ...
Clinical nuclear medicine 37 (7), 637-643, 2012
1522012
Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer
Y Jiang, JF Palma, DB Agus, Y Wang, ME Gross
Clinical chemistry 56 (9), 1492-1495, 2010
1512010
Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis …
ME Gross, MA Zorbas, YJ Danels, R Garcia, GE Gallick, M Olive, ...
Cancer research 51 (5), 1452-1459, 1991
1151991
Targeting the HER-kinase axis in cancer
ME Gross, RL Shazer, DB Agus
Seminars in oncology 31, 9-20, 2004
1122004
PIASy-mediated repression of the androgen receptor is independent of sumoylation
M Gross, R Yang, I Top, C Gasper, K Shuai
Oncogene 23 (17), 3059-3066, 2004
1112004
Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial
JK Dawson, TB Dorff, E Todd Schroeder, CJ Lane, ME Gross, ...
BMC cancer 18, 1-15, 2018
1012018
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer
M Gross, C Higano, A Pantuck, O Castellanos, E Green, K Nguyen, ...
BMC cancer 7, 1-6, 2007
972007
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer
YY Evan, C Massard, ME Gross, MA Carducci, S Culine, G Hudes, ...
Urology 77 (5), 1166-1171, 2011
952011
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design
KW Beekman, AD Colevas, K Cooney, R DiPaola, RL Dunn, M Gross, ...
Clinical genitourinary cancer 4 (4), 299-302, 2006
932006
Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene
CI Müller, CW Miller, WK Hofmann, ME Gross, CS Walsh, N Kawamata, ...
Leukemia research 31 (1), 27-32, 2007
922007
Anterior gradient 2 (AGR2): blood‐based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype
K Kani, PD Malihi, Y Jiang, H Wang, Y Wang, DL Ruderman, DB Agus, ...
The Prostate 73 (3), 306-315, 2013
852013
β-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer
M Gross, I Top, I Laux, J Katz, J Curran, C Tindell, D Agus
Clinical Cancer Research 13 (7), 1979-1986, 2007
812007
Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies
O Ukimura, A Marien, S Palmer, A Villers, M Aron, AL de Castro Abreu, ...
World journal of urology 33, 1669-1676, 2015
762015
The system can't perform the operation now. Try again later.
Articles 1–20